Navigation Links
Cardiome meldet Veröffentlichung positiver Ergebnisse aus Vergleichsstudie von Vernakalant IV mit Propafenon und Flecainid
Date:9/24/2013

VANCOUVER, September 24, 2013 /PRNewswire/ --

- NASDAQ: CRME

- TSX: COM

Die Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) meldete heute die Veröffentlichung positiver Ergebnisse aus einer Open-Label-Studie an Patienten mit Vorhofflimmern, in deren Rahmen die therapeutische Anwendung von intravenös verabreichtem Vernakalant (IV) mit oral verabreichtem Propafenon und oral verabreichtem Flecainid verglichen wurde. Bei den mit Vernakalant behandelten Patienten erfolgte die Konversion in den Sinusrhythmus im Median innerhalb von 12 Minuten, während die Propafenon-Gruppe 151 Minuten und die Flecainid-Gruppe 162 Minuten (p<0,01) benötigte. Die Ergebnisse dieser ersten Vergleichsstudie an diesen drei Wirkstoffen sind in der aktuellen Ausgabe der von Experten begutachteten medizinischen Fachzeitschrift Journal of Atrial Fibrillation publiziert worden.

"Ich bin mit den positiven Ergebnissen dieser Studie sehr zufrieden. Sie zeigen, dass die Konversion zum normalen Sinusrhythmus bei Patienten mit jüngst ausgebrochenem Vorhofflimmern durch die Behandlung mit Vernakalant IV schneller zustande kam als bei Propafenon oder Flecainid. Diese beiden Wirkstoffe werden häufig als antiarrhythmische Medikamente verschrieben," erklärte Dr. med. William Hunter, Chief Executive Officer der Cardiome Pharma Corp. "Die in dieser Einrichtung erzielte schnellere Konversionsrate bei intravenös verabreichtem Vernakalant hat im Vergleich zu den beiden anderen Therapien zu kürzeren Aufenthaltszeiten in der Notaufnahme geführt. Wir sind der Auffassung, dass diese Ergebnisse in weiteren Einrichtungen und ähnlichen Patientengruppen weltweit reproduziert werden können."

"Vernakalant IV ist dank seiner schnell einsetzenden Wirkung in diesem
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
2. Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... its potential to revolutionize the world has attracted ... corporations and small start-ups. The early years of ... projects largely due to the high risks involved, ... budgets earmarked for this evolving technology have been ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... March 31 For the first time, scientists have ... embryo) may be a potential new source of stem ... on February 12, 2009, in Blood , the ... on observations made by other scientists, our research team ...
... GENEVA, Switzerland, March 31 Viroblock SA ... VCCD Tech antiviral nasal spray,formulation is active ... Technology (VCCD Tech) inactivates enveloped,viruses during the ... envelopes. , The ...
... "personal genomics," featuring five of the most outstanding scientists, physicians and ... Bio-IT World Conference & Expo being held April 27-29 at the ... ... (PRWEB) March 31, 2009 -- A plenary panel discussion on the ...
Cached Biology Technology:Amniotic Fluid May Provide New Source of Stem Cells for Future Therapies 2Amniotic Fluid May Provide New Source of Stem Cells for Future Therapies 3Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray 2Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 2Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 3Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 4Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 5
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
(Date:9/18/2014)... their colleagues have built the first smartphone app ... and behavioral trends. In other words, your smartphone ... you don,t -- and how that affects you. ... stress, depression and loneliness to their academic performance, ... for example, to monitor mental health, trigger ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... the upcoming Acoustical Society of America (ASA) meeting in ... Wide pressroom even if they cannot attend in person. ... papers selected from among the 600 talks and posters, ... sound engineering, marine biology, medicine, meteorology, and music. ...
... ambitious European collaboration proposes to set up a new ... requisite skills for accelerating research into cardiovascular disease, the ... deaths, depending on the country. The European Vascular Biology ... conference in Lisbon in December 2007 with a specific ...
... for naming rights to a new owl butterfly species ... bid of $40,800, with proceeds benefiting continued research on ... George Austin and Andrew Warren discovered the new butterfly ... it in this weeks issue of the Bulletin of ...
Cached Biology News:Acoustics World Wide press room now open 2Acoustics World Wide press room now open 3Acoustics World Wide press room now open 4Proposal to step up cardiovascular disease research 2UF's new owl butterfly species naming rights auctioned for $40,800 2UF's new owl butterfly species naming rights auctioned for $40,800 3
...
... Kits synthesize RNA probes with specific activities ... High specific activity, single-stranded RNA probes are ... hybridization, and blot hybridizations. MAXIscript Kits can ... modest amounts of unlabeled RNA (2-4 g/20ul ...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
... liquid controls for monitoring Aldolase tests. ... abnormal) with targeted manufacturing values at ... ± 3 IU/L. 30-day shelf ... 2-8 C. Level 1: 3 x ...
Biology Products: